Study summary

A weekly self-injection that blocks both BAFF and APRIL cut protein in the urine by almost half

ORIGIN 3 trial (atacicept) · 203 people in interim analysis, phase 3 · Published November 2025, New England Journal of Medicine; FDA accelerated approval July 2026

45.7%drop in urine protein at 36 weeks, vs 6.8% with placebo

What was tested

Atacicept, a once-weekly home injection that blocks both BAFF and APRIL, against placebo, for IgA nephropathy.

What they found

Urine protein fell 45.7% vs 6.8% with placebo.
Side effects were mostly mild or moderate.

What it means

A second drug aimed at the immune cause of the disease, approved in July 2026.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.